title: Comparisons of alloreactive potential of clinical hematopoietic grafts.
abstract: BACKGROUND
  We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients.
  
  
  METHODS
  Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS).
  
  
  RESULTS
  For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS-free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells.
  
  
  CONCLUSIONS
  The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-5001, USA. wileung@welchlink.welch.jhu.edu
authors.forename: W
authors.initials: W
authors.lastname: Leung
authors.forename: M
authors.initials: M
authors.lastname: Ramírez
authors.forename: G
authors.initials: G
authors.lastname: Mukherjee
authors.forename: E J
authors.initials: EJ
authors.lastname: Perlman
authors.forename: C I
authors.initials: CI
authors.lastname: Civin
mesh_terms: D000328:Adult; D000818:Animals; D001402:B-Lymphocytes / Q000637:transplantation; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000097:blood; D002678:Chimera / Q000276:immunology; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D006086:Graft vs Host Disease / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008212:Lymphocyte Depletion; D051379:Mice; D011247:Pregnancy; D012016:Reference Values; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000473:pathology / Q000637:transplantation; D014183:Transplantation, Heterologous / Q000276:immunology*